XNYS · Healthcare · Diagnostics & Research
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-23 | Q1 2026 | 5.23 | 5.44 | +4.02% | $11.01B | ✅ Beat | +1.17% | +2.63% | -3.95% |
| 2026-01-29 | Q4 2025 | 6.44 | 6.57 | +2.02% | $12.21B | ✅ Beat | +1.05% | -8.41% | -12.00% |
| 2025-10-22 |
| Q3 2025 |
| 5.50 |
| 5.79 |
| +5.27% |
| $11.12B |
| ✅ Beat |
| — |
| — |
| — |
| 2025-07-23 | Q2 2025 | 5.23 | 5.36 | +2.49% | $10.86B | ✅ Beat | — | — | — |
| 2025-04-23 | Q1 2025 | 5.10 | 5.15 | +0.98% | $10.36B | ✅ Beat | — | — | — |
| 2025-01-30 | Q4 2024 | 5.94 | 6.10 | +2.69% | $11.39B | ✅ Beat | — | — | — |
| 2024-10-23 | Q3 2024 | 5.24 | 5.28 | +0.76% | $10.60B | ✅ Beat | — | — | — |
| 2024-07-24 | Q2 2024 | 5.12 | 5.37 | +4.88% | $10.54B | ✅ Beat | — | — | — |
Showing last 8 quarters.